Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29598912 | 0.86 | LMNA (0.49) | ALDH1A1POLBSMN1; SMN2TSHRLMNA | |
| SCHEMBL4767619 | 0.84 | RAB9A (0.40) | POLBLMNAMEN1KMT2ATDP1 | |
| SCHEMBL938094 | 0.83 | GAA (0.42) | ALDH1A1POLBHTTSMN1; SMN2GAA | |
| SCHEMBL29155813 | 0.83 | ALDH1A1 (0.43) | ALDH1A1POLBHTTSMN1; SMN2GAA | |
| SCHEMBL2379075 | 0.83 | TSHR (0.41) | ALDH1A1SMN1; SMN2TSHRL3MBTL1LMNA | |
| SCHEMBL160444 | 0.82 | GAA (0.41) | ALDH1A1POLBHTTSMN1; SMN2GAA | |
| SCHEMBL13711179 | 0.82 | GAA (0.41) | ALDH1A1POLBHTTSMN1; SMN2GAA | |
| SCHEMBL4364361 | 0.82 | GAA (0.41) | ALDH1A1POLBHTTSMN1; SMN2GAA | |
| SCHEMBL13494279 | 0.82 | GAA (0.41) | ALDH1A1POLBHTTSMN1; SMN2GAA | |
| SCHEMBL742700 | 0.82 | ALDH1A1 (0.44) | ALDH1A1POLBHTTSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2021-05-06 | — | — | US | disclosed |
| CN-107820494-B | Nuclear receptor modulators | 艾伯维公司 | 2020-10-16 | — | — | CN | disclosed |
| EP-3636643-A1 | NUCLEAR RECEPTOR MODULATORS (ROR) FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3275870-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20190055196-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2019-02-21 | — | — | US | disclosed |
| US-10106501-B2 | Nuclear receptor modulators | ABBVIE INC. (US) | 2018-10-23 | — | — | US | disclosed |
| EP-3307734-A1 | NUCLEAR RECEPTOR MODULATORS | AbbVie Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| CN-107820494-A | Nuclear receptor modulators | 艾伯维公司 | 2018-03-20 | — | — | CN | disclosed |
| EP-3275870-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| WO-2002085886-A2 | CHIRAL, BROAD-SPECTRUM ANTIBACTERIAL 7-SUBSTITUTED PIPERIDINO-QUINOLONE CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS | WOCKHARDT LIMITED (IN) | 2002-10-31 | — | — | WO | disclosed |
| US-5292738-A | Anti-virally active pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-03-08 | — | — | US | disclosed |
| US-5157035-A | Viricides | JANSSEN PHARMACEUTICA N. V. (BE) | 1992-10-20 | — | — | US | disclosed |
| US-5001125-A | Anti-virally active pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-03-19 | — | — | US | disclosed |
| EP-0156433-B1 | ANTI-VIRALLY ACTIVE PYRIDAZINAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-02-27 | — | — | EP | disclosed |
| EP-0156433-A2 | Anti-virally active pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-10-02 | — | — | EP | disclosed |
| US-4478837-A | HYPOTENSIVE AGENTS | SANDOZ LTD. (CH) | 1984-10-23 | — | — | US | disclosed |
| US-4263298-A | Hydrazino bicyclic pyridazines as hypertensives | SANDOZ LTD. (CH) | 1981-04-21 | — | — | US | disclosed |
| US-4181723-A | HYPOTENSIVE AGENTS | SANDOZ LTD. (CH) | 1980-01-01 | — | — | US | disclosed |
| US-3954754-A | ANTIHYPERTENSIVES | SANDOZ LTD. (CH) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106501-B2 | Nuclear receptor modulators | NR1I2, NR1H2, NR5A2 | ALDH1A1 940/4885POLB 3941/4885HTT 4447/4885 |
| US-20210130293-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | ALDH1A1 940/4885POLB 3941/4885HTT 4447/4885 |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | ALDH1A1 940/4885POLB 3941/4885HTT 4447/4885 |
| US-20190055196-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | ALDH1A1 940/4885POLB 3941/4885HTT 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.